Free Trial
NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Lixte Biotechnology logo
$2.63 +0.61 (+30.15%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$2.38 -0.25 (-9.66%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lixte Biotechnology Stock (NASDAQ:LIXT)

Key Stats

Today's Range
$2.44
$4.25
50-Day Range
$0.71
$2.63
52-Week Range
$0.64
$4.25
Volume
64.13 million shs
Average Volume
650,780 shs
Market Capitalization
$7.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Lixte Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

LIXT MarketRank™: 

Lixte Biotechnology scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Lixte Biotechnology.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lixte Biotechnology is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lixte Biotechnology is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Lixte Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    0.22% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently decreased by 55.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lixte Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Lixte Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.22% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently decreased by 55.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lixte Biotechnology has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Lixte Biotechnology this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for LIXT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.80% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.10% of the stock of Lixte Biotechnology is held by institutions.

  • Read more about Lixte Biotechnology's insider trading history.
Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

LIXT Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

LIXT Stock Analysis - Frequently Asked Questions

Lixte Biotechnology's stock was trading at $2.03 on January 1st, 2025. Since then, LIXT shares have increased by 29.5% and is now trading at $2.6290.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter.

Lixte Biotechnology's stock reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Lixte Biotechnology (LIXT) raised $7 million in an IPO on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO.

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
5/12/2025
Today
7/06/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIXT
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.19) per share
Price / Book
-2.21

Miscellaneous

Free Float
2,287,000
Market Cap
$7.06 million
Optionable
Not Optionable
Beta
0.31
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:LIXT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners